Literature DB >> 32201927

BDNF improves axon transportation and rescues visual function in a rodent model of acute elevation of intraocular pressure.

Rui Du1, Xu Wang1, Shigang He2,3,4.   

Abstract

Optic neuropathies lead to blindness; the common pathology is the degeneration of axons of the retinal ganglion cells. In this study, we used a rat model of retinal ischemia-reperfusion and a one-time intravitreal brain-derived neurotrophic factor (BDNF) injection; then we examined axon transportation function, continuity, physical presence of axons in different part of the optic nerve, and the expression level of proteins involved in axon transportation. We found that in the disease model, axon transportation was the most severely affected, followed by axon continuity, then the number of axons in the distal and proximal optic nerve. BDNF treatment relieved all reductions and significantly restored function. The molecular changes were more minor, probably due to massive gliosis of the optic nerve, so interpretation of protein expression data should be done with some caution. The process in this acute model resembles a fast-forward of changes in the chronic model of glaucoma. Therefore, impairment in axon transportation appears to be a common early process underlying different optic neuropathies. This research on effective intervention can be used to develop interventions for all optic neuropathies targeting axon transportation.

Entities:  

Keywords:  acute elevation of IOP; axon continuity; axon transportation; contrast sensitivity; rat; visual acuity

Mesh:

Substances:

Year:  2020        PMID: 32201927     DOI: 10.1007/s11427-019-1567-0

Source DB:  PubMed          Journal:  Sci China Life Sci        ISSN: 1674-7305            Impact factor:   6.038


  44 in total

Review 1.  Axon degeneration mechanisms: commonality amid diversity.

Authors:  Michael Coleman
Journal:  Nat Rev Neurosci       Date:  2005-11       Impact factor: 34.870

Review 2.  Intracellular transport and kinesin superfamily proteins, KIFs: structure, function, and dynamics.

Authors:  Nobutaka Hirokawa; Yasuko Noda
Journal:  Physiol Rev       Date:  2008-07       Impact factor: 37.312

3.  The glial cell modulator ibudilast attenuates neuroinflammation and enhances retinal ganglion cell viability in glaucoma through protein kinase A signaling.

Authors:  Jorge L Cueva Vargas; Nicolas Belforte; Adriana Di Polo
Journal:  Neurobiol Dis       Date:  2016-05-06       Impact factor: 5.996

4.  Structural basis of glaucoma: the fortified astrocytes of the optic nerve head are the target of raised intraocular pressure.

Authors:  Chao Dai; Peng T Khaw; Zheng Qin Yin; Daqing Li; Geoffrey Raisman; Ying Li
Journal:  Glia       Date:  2011-09-21       Impact factor: 7.452

Review 5.  The 'dying back' process. A common denominator in many naturally occurring and toxic neuropathies.

Authors:  J B Cavanagh
Journal:  Arch Pathol Lab Med       Date:  1979-12       Impact factor: 5.534

6.  Distal axonopathy with structural persistence in glaucomatous neurodegeneration.

Authors:  Samuel D Crish; Rebecca M Sappington; Denise M Inman; Philip J Horner; David J Calkins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-01       Impact factor: 11.205

7.  Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy.

Authors:  C Delettre; G Lenaers; J M Griffoin; N Gigarel; C Lorenzo; P Belenguer; L Pelloquin; J Grosgeorge; C Turc-Carel; E Perret; C Astarie-Dequeker; L Lasquellec; B Arnaud; B Ducommun; J Kaplan; C P Hamel
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

8.  OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28.

Authors:  C Alexander; M Votruba; U E Pesch; D L Thiselton; S Mayer; A Moore; M Rodriguez; U Kellner; B Leo-Kottler; G Auburger; S S Bhattacharya; B Wissinger
Journal:  Nat Genet       Date:  2000-10       Impact factor: 38.330

9.  Failure of axonal transport induces a spatially coincident increase in astrocyte BDNF prior to synapse loss in a central target.

Authors:  S D Crish; J D Dapper; S E MacNamee; P Balaram; T N Sidorova; W S Lambert; D J Calkins
Journal:  Neuroscience       Date:  2012-11-14       Impact factor: 3.590

10.  Progressive ganglion cell degeneration precedes neuronal loss in a mouse model of glaucoma.

Authors:  Brian P Buckingham; Denise M Inman; Wendi Lambert; Ericka Oglesby; David J Calkins; Michael R Steele; Monica L Vetter; Nicholas Marsh-Armstrong; Philip J Horner
Journal:  J Neurosci       Date:  2008-03-12       Impact factor: 6.167

View more
  5 in total

1.  Dynamic changes of inducible nitric oxide synthase expression in rat's retina and its role on blood-retinal barrier injury after acute high intraocular pressure.

Authors:  Min Li; Ju-Fang Huang; Yi Li; Jing Shen; Lu-Jia Yang; Qian Chen; Quan-Peng Zhang; Xi-Nan Yi
Journal:  Int J Ophthalmol       Date:  2022-07-18       Impact factor: 1.645

2.  Receptor-ligand supplementation via a self-cleaving 2A peptide-based gene therapy promotes CNS axonal transport with functional recovery.

Authors:  Tasneem Z Khatib; Andrew Osborne; Sujeong Yang; Zara Ali; Wanyi Jia; Ilya Manyakin; Katie Hall; Robert Watt; Peter S Widdowson; Keith R Martin
Journal:  Sci Adv       Date:  2021-03-31       Impact factor: 14.136

Review 3.  The Role of Axonal Transport in Glaucoma.

Authors:  Mariana Santana Dias; Xiaoyue Luo; Vinicius Toledo Ribas; Hilda Petrs-Silva; Jan Christoph Koch
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

4.  Stimulation of C-Kit+ Retinal Progenitor Cells by Stem Cell Factor Confers Protection Against Retinal Degeneration.

Authors:  Xi Chen; Shanshan Li; Xiaoli Liu; Jingjie Zhao; Lanting Wu; Ran You; Yanling Wang
Journal:  Front Pharmacol       Date:  2022-03-31       Impact factor: 5.810

5.  Evaluations of aqueous humor protein markers in different types of glaucoma.

Authors:  Haiyan Chen; Gang Zheng; Huijie Chen; Lu Li; Zhuojun Xu; Li Xu
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.